Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: effect of lymphadenectomy. 2009

Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
CI Hayashi Immunotherapy Clinic and Research Institute, Osaka, Japan. ci-hayashi@sutv.zaq.ne.jp

The significance of lymphadenectomy in surgery for various kinds of cancer has been widely debated, particularly in the gynecological field. The cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) has been used as an effective adjuvant for immunotherapy of a variety of cancer patients. Here we tested the immunological importance of lymph nodes in treatment of ovarian cancer patients with BCG-CWS. After surgical removal of tumors, 73 ovarian cancer patients were intracutaneously inoculated with BCG-CWS in the antigen-unloaded state in the upper arm at 4-week intervals at a dosage of 2-200 microg. Significant correlation of lymphadenectomy and reduced survival of patients was observed (stages I, II, III, IV; hazard ratio 2.38, 95% confidence interval 1.02-5.12, Cox regression model). Lymphadenectomy also compromised with induction of interferon-gamma. In view of the importance of the role of lymph nodes in stimulation of Toll-like receptors by BCG-CWS, it is suggested that lymph nodes should be kept as much as possible to preserve the patient's immunity against cancer. Application of these results to surgery for other cancers should be considered.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
August 1979, Cancer research,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
January 1976, Annals of the New York Academy of Sciences,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
December 2022, Medicine,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
January 1988, The Journal of reproductive medicine,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
December 2023, Cureus,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
December 2000, Infection and immunity,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
November 2007, Proteomics,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
June 2017, Journal of pharmacy practice,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
January 2011, Surgical neurology international,
Akira Hayashi, and Yuichi Nishida, and Saiji Yoshii, and Seo Young Kim, and Hirotsugu Uda, and Toshimitsu Hamasaki
February 1997, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!